Jay Olson
Stock Analyst at Oppenheimer
(3.48)
# 826
Out of 4,829 analysts
240
Total ratings
39.15%
Success rate
6.03%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $75 | $40.42 | +85.55% | 9 | May 8, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $25 → $21 | $1.14 | +1,742.11% | 2 | May 7, 2025 | |
| NKTR Nektar Therapeutics | Upgrades: Outperform | $6 | $0.59 | +919.19% | 6 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $50 → $42 | $14.37 | +192.28% | 4 | Mar 3, 2025 | |
| PRTA Prothena Corporation | Maintains: Outperform | $58 → $62 | $7.43 | +734.45% | 13 | Feb 7, 2025 | |
| EXEL Exelixis | Downgrades: Perform | $41 → $33 | $36.17 | -8.76% | 6 | Jan 24, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $60 → $40 | $8.12 | +392.61% | 9 | Jan 13, 2025 | |
| QTTB Q32 Bio | Maintains: Outperform | $80 → $20 | $1.55 | +1,190.32% | 2 | Dec 11, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $30 | $3.26 | +820.25% | 1 | Dec 6, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $17 → $20 | $3.04 | +557.89% | 2 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $15 | $1.80 | +733.33% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $255 | $118.17 | +115.79% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $9 → $8 | $6.57 | +21.77% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $58.98 | +39.03% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $299.69 | +16.79% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $2.75 | +264.30% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $27.55 | +400.91% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.93 | +314.51% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 | $8.34 | +475.54% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $265.86 | +42.93% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $115.71 | +89.27% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $1.45 | +727.59% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.17 | +467.82% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.87 | +1,047.45% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $35.62 | +166.70% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $19 | $17.44 | +8.94% | 14 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.81 | +1,281.22% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $32.30 | +132.23% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.30 | +2,889.04% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 | $4.52 | +1,669.91% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $7.71 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $50 | $1.12 | +4,364.29% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $5.27 | +298.48% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.42 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.46 | +381.10% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.46 | - | 3 | Jul 11, 2017 |
Revolution Medicines
May 8, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $40.42
Upside: +85.55%
Immuneering
May 7, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $1.14
Upside: +1,742.11%
Nektar Therapeutics
Mar 14, 2025
Upgrades: Outperform
Price Target: $6
Current: $0.59
Upside: +919.19%
Denali Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $14.37
Upside: +192.28%
Prothena Corporation
Feb 7, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $7.43
Upside: +734.45%
Exelixis
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $36.17
Upside: -8.76%
Intellia Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $8.12
Upside: +392.61%
Q32 Bio
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $1.55
Upside: +1,190.32%
Sagimet Biosciences
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $3.26
Upside: +820.25%
Terns Pharmaceuticals
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $3.04
Upside: +557.89%
Nov 18, 2024
Maintains: Outperform
Price Target: $33 → $15
Current: $1.80
Upside: +733.33%
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $118.17
Upside: +115.79%
Oct 30, 2024
Maintains: Perform
Price Target: $9 → $8
Current: $6.57
Upside: +21.77%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $58.98
Upside: +39.03%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $299.69
Upside: +16.79%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $2.75
Upside: +264.30%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $27.55
Upside: +400.91%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.93
Upside: +314.51%
Aug 7, 2024
Maintains: Outperform
Price Target: $48
Current: $8.34
Upside: +475.54%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $265.86
Upside: +42.93%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $115.71
Upside: +89.27%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $1.45
Upside: +727.59%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.17
Upside: +467.82%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.87
Upside: +1,047.45%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $35.62
Upside: +166.70%
May 6, 2024
Maintains: Perform
Price Target: $19
Current: $17.44
Upside: +8.94%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $1.81
Upside: +1,281.22%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $32.30
Upside: +132.23%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.30
Upside: +2,889.04%
Mar 7, 2024
Maintains: Outperform
Price Target: $80
Current: $4.52
Upside: +1,669.91%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $7.71
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $120 → $50
Current: $1.12
Upside: +4,364.29%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $5.27
Upside: +298.48%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.42
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.46
Upside: +381.10%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.46
Upside: -